FIVE PRIME THERAPEUTICS INC's ticker is FPRX and the CUSIP is 33830X104. A total of 113 filers reported holding FIVE PRIME THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 469.50 and the average weighting 0.0%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2021 | $705,000 | +127.4% | 18,705 | +2.8% | 0.00% | +100.0% |
Q4 2020 | $310,000 | +313.3% | 18,197 | +13.6% | 0.00% | – |
Q3 2020 | $75,000 | -25.0% | 16,015 | -2.2% | 0.00% | – |
Q2 2020 | $100,000 | +117.4% | 16,380 | -18.9% | 0.00% | – |
Q1 2020 | $46,000 | -53.1% | 20,190 | -5.5% | 0.00% | – |
Q4 2019 | $98,000 | +16.7% | 21,357 | -1.9% | 0.00% | – |
Q3 2019 | $84,000 | -35.4% | 21,768 | +1.3% | 0.00% | -100.0% |
Q2 2019 | $130,000 | -54.7% | 21,490 | +0.5% | 0.00% | 0.0% |
Q1 2019 | $287,000 | +40.0% | 21,386 | -3.1% | 0.00% | 0.0% |
Q4 2018 | $205,000 | -33.9% | 22,079 | -0.8% | 0.00% | 0.0% |
Q3 2018 | $310,000 | -9.4% | 22,249 | +2.9% | 0.00% | 0.0% |
Q2 2018 | $342,000 | -5.3% | 21,621 | +2.8% | 0.00% | 0.0% |
Q1 2018 | $361,000 | -10.0% | 21,026 | +14.8% | 0.00% | 0.0% |
Q4 2017 | $401,000 | -46.2% | 18,312 | +0.5% | 0.00% | -66.7% |
Q3 2017 | $746,000 | +46.9% | 18,226 | +8.1% | 0.00% | +50.0% |
Q2 2017 | $508,000 | -15.5% | 16,863 | +1.5% | 0.00% | 0.0% |
Q1 2017 | $601,000 | -22.7% | 16,614 | +7.1% | 0.00% | -33.3% |
Q4 2016 | $777,000 | -99.9% | 15,514 | -0.3% | 0.00% | 0.0% |
Q3 2016 | $816,482,000 | +27.1% | 15,555 | +0.1% | 0.00% | 0.0% |
Q2 2016 | $642,248,000 | +13.3% | 15,532 | +11.4% | 0.00% | +50.0% |
Q1 2016 | $567,000,000 | -2.1% | 13,947 | 0.0% | 0.00% | 0.0% |
Q4 2015 | $579,000,000 | +290854.8% | 13,947 | +7.5% | 0.00% | +100.0% |
Q3 2015 | $199,000 | -99.9% | 12,969 | +0.1% | 0.00% | 0.0% |
Q2 2015 | $321,777,000 | +25.8% | 12,954 | +15.8% | 0.00% | 0.0% |
Q1 2015 | $255,692,000 | -12.6% | 11,190 | +3.2% | 0.00% | 0.0% |
Q4 2014 | $292,680,000 | +121.4% | 10,840 | -3.8% | 0.00% | 0.0% |
Q3 2014 | $132,197,000 | -24.6% | 11,270 | -0.1% | 0.00% | 0.0% |
Q2 2014 | $175,357,000 | +133.5% | 11,277 | +195.2% | 0.00% | – |
Q1 2014 | $75,101,000 | +20.0% | 3,820 | +2.5% | 0.00% | – |
Q4 2013 | $62,593,000 | – | 3,728 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Eventide Asset Management | 601,000 | $24,587,000 | 1.39% |
HealthCor Management, L.P. | 1,010,930 | $41,357,000 | 1.39% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 86,500 | $3,535,000 | 1.38% |
PURA VIDA INVESTMENTS, LLC | 75,000 | $3,068,000 | 0.90% |
BB BIOTECH AG | 777,500 | $31,808,000 | 0.88% |
AWM Investment Company, Inc. | 100,000 | $4,091,000 | 0.71% |
Granite Point Capital Management, L.P. | 50,000 | $2,046,000 | 0.43% |
Rock Springs Capital Management LP | 217,700 | $8,906,000 | 0.41% |
Crestline Management, LP | 50,919 | $2,083,000 | 0.29% |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,432,700 | $99,522,000 | 0.24% |